Literature DB >> 3063914

Purified verotoxins of Escherichia coli O157:H7 decrease prostacyclin synthesis by endothelial cells.

H Karch1, M Bitzan, R Pietsch, K O Stenger, H von Wulffen, J Heesemann, R Düsing.   

Abstract

Two immunologically distinct verotoxins purified from Escherichia coli C600, lysogenized with distinct temperate phages from E. coli strain 933 of serotype O157:H7, were compared by SDS-PAGE and different biological assays. The two toxins termed verotoxin 1 (VT1) and verotoxin 2 (VT2) differing in molecular weight exhibited similar biological activities. Both preparations were toxic for HeLa cells and lethal for mice. Epidemiological evidence of verotoxinogenesis in some cases of hemolytic-uremic syndrome (HUS) and the recent observations of inadequate prostacyclin production by endothelial cells associated with HUS prompted us to study the effect of purified verotoxins on prostacyclin synthesis in rat aortic tissue. Our results demonstrate a significant reduction of prostacyclin by both toxins at picomolar levels. The suppression of prostacyclin release by a lower concentration of VT2 as compared with VT1 reflects the relative potencies of these toxins in HeLa cell toxicity and mouse lethality. The results suggest an effect of verotoxins on endothelial cells and support the concept of these toxins as virulence factors in E. coli.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3063914     DOI: 10.1016/0882-4010(88)90024-1

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  12 in total

1.  Shiga toxin 1 from Escherichia coli blocks activation and proliferation of bovine lymphocyte subpopulations in vitro.

Authors:  C Menge; L H Wieler; T Schlapp; G Baljer
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 2.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

3.  Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls.

Authors:  M Bitzan; M Klemt; R Steffens; D E Müller-Wiefel
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

Review 4.  The shigella paradigm and colitis due to enterohaemorrhagic Escherichia coli.

Authors:  D W Acheson; G T Keusch
Journal:  Gut       Date:  1994-07       Impact factor: 23.059

5.  Frequent loss of Shiga-like toxin genes in clinical isolates of Escherichia coli upon subcultivation.

Authors:  H Karch; T Meyer; H Rüssmann; J Heesemann
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

Review 6.  Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes.

Authors:  B S Kaplan; T G Cleary; T G Obrig
Journal:  Pediatr Nephrol       Date:  1990-05       Impact factor: 3.714

7.  Evaluation of oligonucleotide probes for identification of shiga-like-toxin-producing Escherichia coli.

Authors:  H Karch; T Meyer
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

Review 8.  Prostacyclin in diarrhoea-associated haemolytic uraemic syndrome.

Authors:  C M Taylor; C J Lote
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

9.  Expression of A and B subunits of Shiga-like toxin II as fusions with glutathione S-transferase and their potential for use in seroepidemiology.

Authors:  F Gunzer; H Karch
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

10.  Shiga-like toxin II-related cytotoxins in Citrobacter freundii strains from humans and beef samples.

Authors:  H Schmidt; M Montag; J Bockemühl; J Heesemann; H Karch
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.